Filing Flows › BridgeBio Pharma (BBIO) › Royalty revenue revenue
BridgeBio Pharma (BBIO) Royalty revenue revenue by quarter
BridgeBio Pharma's Royalty revenue revenue was $20.5M in Q3 2026 (third quarter 2026), +33% from Q2 2026. Over the last 5 quarters it ranged from $4.3M (Q3 2025) to $20.5M (Q3 2026).
| Quarter | Royalty revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $20.5M | +33% | +379% |
| Q2 2026 | $15.4M | +62% | — |
| Q1 2026 | $9.5M | +80% | — |
| Q4 2025 | $5.3M | +23% | — |
| Q3 2025 | $4.3M | — | — |
Q3 2026 at a glance
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is BridgeBio Pharma's Royalty revenue revenue?
BridgeBio Pharma's Royalty revenue revenue was $20.5M in Q3 2026 (third quarter 2026), +33% from Q2 2026.
How has BridgeBio Pharma's Royalty revenue revenue changed?
Over the last 5 quarters it ranged from $4.3M (Q3 2025) to $20.5M (Q3 2026).